

Table EU Approved / positive opinion biosimilars by molecule June 2021

(not available in all EU-countries) (status CHMP-meeting June 25, 2021, 69 products, from which 2 pending EC approval*)

Molecule	Reference	Biosimilar(s)
Adalimumab	Humira	Amgevita, Amsparity, Halimatoz, Hefiya, Hulio, Hyrimoz, Idacio, Imraldi; Yuflyma (new formulation)
bevacizumab	Avastin	MVasi, Zirabev, Aybintio, Equidacent; positive opinion: Onbevzi, Alymsys, Oyavas, Abevmy*, Lextemy*.
Enoxaparine	Clexane	Inhixa
Epoetine alfa	Eprex	Absaemed, Binocrit, Epoetin alfa Hexal, Retacrit, Silapo
Etanercept	Enbrel	Benepali, Erelzi, Nepexto
Filgrastim	Neupogen	Accofil, Filgrastim Hexal, Grastofil, Nivestim, Ratiograstim, Tevagrastim, Zarzio
Follitropin alfa	Gonal-f	Bemfola, Ovaleap
Infliximab	Remicade	Flixabi, Inflectra, Remsima, Zessly
Insulin Aspart	Novo Rapid	Insulin Aspart Sanofi; positive opinion: Kixelle
Insulin glargine	Lantus	Abasaglar, Semglee
Insulin Lispro	Humalog	Insulin Lispro Sanofi
Pegfilgrastim	Neulasta	Cegfila, Fulphila, Grasustek, Pelgraz, Pelmeg, Udenyca, Ziextenzo, Nyvepria
Rituximab	Mabthera IV	Blitzima, Ritemvia, Rixathon, Riximyo, Ruxience, Truxima
Somatropine	Genotropin	Omnitrope
Teriparatide	Forsteo	Movymia, Terrosa, Livogiga, Qutavina.
Trastuzumab	Herceptin IV	Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera, Zercepac

Source: EMA website

https://www.ema.europa.eu/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_a_medicine/field_ema_med_status/authorised36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar

Accessed: June 25, 2021_LB

For a comparison with US/FDA (March 2021) see:

<https://www.biosimilarsip.com/2021/03/08/how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline-6/>

FDA approved biosimilars (status June 17, 2021)

<https://biosimilarsrr.com/us-biosimilar-filings/>

12 Biosimilar-products in the licensing pipeline at EMA (Status: June 3, 2021).

Adalimumab (2x); Bevacizumab (1x), Insuline aspart (1x), Insulin Human (rdDNA) 1x; pegfilgrastim (1x), ranibizumab (1x), teriparatide (3x), trastuzumab (2x).

2021_06_12 Table EU licensed biosimilars by molecule_June_2021agv